Adial Pharmaceuticals (ADIL) News Today $0.40 0.00 (-0.90%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.41 +0.01 (+2.91%) As of 10/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Maxim Group Upgrades Adial Pharmaceuticals (NASDAQ:ADIL) to "Buy"October 2 at 2:32 AM | americanbankingnews.comMaxim Group Upgrades Adial Pharmaceuticals (ADIL)October 1 at 8:56 AM | msn.comAnalysts Set Expectations for ADIL Q1 EarningsSeptember 27, 2025 | americanbankingnews.comQ3 EPS Estimates for ADIL Cut by Litchfield Hills ResearchSeptember 27, 2025 | americanbankingnews.comAdial announces receipt of final meeting minuts from EOP2 meeting with FDASeptember 16, 2025 | msn.comAdial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04September 16, 2025 | globenewswire.comAdial granted a 180 calendar day extension by Nasdaq to regain complianceSeptember 3, 2025 | msn.comAdial Pharmaceuticals Receives 180-Day Extension to Regain Nasdaq Compliance with Minimum Bid Price RequirementSeptember 3, 2025 | quiverquant.comQAdial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price RuleSeptember 3, 2025 | globenewswire.comAdial Hails Senate Moves on TrialsAugust 20, 2025 | baystreet.caAdial Pharmaceuticals Applauds U.S. Senate Support for Expanding Clinical Trial Endpoints in Alcohol Use Disorder TreatmentsAugust 20, 2025 | quiverquant.comQAdial Pharmaceuticals expects cash to fund operations into Q2 of 2026August 15, 2025 | msn.comAdial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comAdial Pharmaceuticals Enters New Sales AgreementAugust 9, 2025 | theglobeandmail.comAdial Pharmaceuticals Inc.August 8, 2025 | barrons.comAdial Pharmaceuticals Completes Successful EOP2 FDA MeetingAugust 6, 2025 | globenewswire.comAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing RequirementJuly 16, 2025 | finance.yahoo.comAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing RequirementJuly 16, 2025 | globenewswire.comAdial Pharmaceuticals Files PCT Patent Application to Protect Core ...July 11, 2025 | morningstar.comMAdial Pharmaceuticals Files Update to Provisional Patent ... - NasdaqJuly 11, 2025 | nasdaq.comAdial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045July 9, 2025 | globenewswire.comADIL - Adial Pharmaceuticals Inc News - MorningstarJuly 2, 2025 | morningstar.comMAdial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product SupplyJune 25, 2025 | globenewswire.comAdial Pharmaceuticals, Inc. (ADIL) Stock Price, Quote, News & Analysis | Seeking AlphaJune 24, 2025 | seekingalpha.comAdial Pharmaceuticals prices $3.6 million public offeringJune 18, 2025 | investing.comAdial Pharmaceuticals Announces Pricing of $3.6 Million Public OfferingJune 17, 2025 | finance.yahoo.comAdial Pharmaceuticals Advances Toward Phase 3 Development for AD04June 11, 2025 | finance.yahoo.comAdial Pharmaceuticals Reports First Quarter 2025 Business Update and Financial ResultsMay 17, 2025 | nasdaq.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finanznachrichten.deAdial Pharmaceuticals Receives Development Milestone Payment from Adovate Following Phase 1 Clinical Trial Initiation for Asthma TreatmentMay 15, 2025 | nasdaq.comAdial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comAdial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 StudyMay 13, 2025 | globenewswire.comAdial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug AdministrationMay 9, 2025 | finance.yahoo.comAdial Pharmaceuticals raises $2.75MMay 7, 2025 | bizjournals.comAdial Pharmaceuticals raises $2.75MMay 7, 2025 | bizjournals.comAdial Pharmaceuticals Secures Patent for Novel Treatment of Alcohol and Opioid Disorders Using AD04 in Genetically Identified PatientsMay 3, 2025 | nasdaq.comAdial Pharmaceuticals secures patent for addiction treatmentMay 2, 2025 | investing.com1ADIL : EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent...May 2, 2025 | benzinga.comAdial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross ProceedsMay 2, 2025 | globenewswire.comAdial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use DisordersMay 1, 2025 | globenewswire.comAdial Pharmaceuticals appoints new COO Tony GoodmanMarch 23, 2025 | uk.investing.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business UpdateMarch 4, 2025 | finanznachrichten.deAdial Pharmaceuticals expects cash to fund operations into 2H of 2025March 4, 2025 | markets.businessinsider.comAdial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business UpdateMarch 4, 2025 | globenewswire.comAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 26, 2025 | finanznachrichten.deAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 25, 2025 | markets.businessinsider.comAdial says FDA feedback confirms proposed strategy to AD04 Phase 3 formulationFebruary 25, 2025 | markets.businessinsider.comAdial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04February 25, 2025 | globenewswire.comAdial awarded patent covering genetic approach to alcoholism by USPTOFebruary 19, 2025 | markets.businessinsider.comAdial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug DependenciesFebruary 19, 2025 | globenewswire.com Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADIL Media Mentions By Week ADIL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADIL News Sentiment▼0.270.54▲Average Medical News Sentiment ADIL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADIL Articles This Week▼31▲ADIL Articles Average Week Get the Latest News and Ratings for ADIL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Adial Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Klotho Neurosciences News AlloVir News Kezar Life Sciences News Dare Bioscience News Cadrenal Therapeutics News Rein Therapeutics News Moleculin Biotech News Exicure News MIRA Pharmaceuticals News Passage Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADIL) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADIL Stock Alerts